OCS
Oculis Holding AG
Price Chart
Latest Quote
$11.90
+0.23 (+1.97%)
Current Price
| Previous Close | $11.67 |
| Open | $11.41 |
| Day High | $11.94 |
| Day Low | $11.36 |
| Volume | 139,384 |
Stock Information
Note: Financial values converted from CHF to USD
| Shares Outstanding | 60.39M |
| Total Debt | $2.78M |
| Cash Equivalents | $274.30M |
| Revenue | $1.39M |
| Net Income | $-116.86M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $718.62M |
| EPS (TTM) | $-2.09 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $484.94M |
| Sales | $1.39M |
| Income | $-116.86M |
| Book/sh | $4.07 |
| Cash/sh | $3.68 |
| Employees | 60 |
Financial Ratios
| Quick Ratio | 5.10 |
| Current Ratio | 5.18 |
| Debt/Eq | 1.14 |
Returns & Margins
| ROA | -23.27% |
| ROE | -52.66% |
| Operating Margin | -10396.17% |
Ownership
| Insider Ownership | 3.51% |
| Institutional Ownership | 38.52% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.88 |
| P/S | 639.91 |
| P/B | 2.92 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $37.44 |
Technical Indicators
| SMA20 | $14.94 |
| SMA50 | $23.14 |
| SMA200 | $22.77 |
| RSI | 46.30 |
| ATR | 0.8711 |
| Shares Float | 52.13M |
| Short Float | 1.25% |
| Short Ratio | 1.30 |
| Volatility | 0.13 |
| Rel Volume | 0.11 |
Performance History
| Week | +2.50% |
| Month | -61.61% |
| Quarter | -51.63% |
| 6 Months | -38.91% |
| YTD | -40.50% |
| Year | -38.28% |
| 3 Years | -2.86% |
| 5 Years | +22.68% |
| 10 Years | +22.68% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $11.90 | 139,384 |
| 2026-06-22 | $11.67 | 480,700 |
| 2026-06-18 | $11.22 | 772,300 |
| 2026-06-17 | $11.30 | 581,100 |
| 2026-06-16 | $11.45 | 615,700 |
| 2026-06-15 | $11.61 | 759,800 |
| 2026-06-12 | $11.09 | 406,800 |
| 2026-06-11 | $11.00 | 427,900 |
| 2026-06-10 | $10.97 | 644,700 |
| 2026-06-09 | $10.98 | 1,426,000 |
| 2026-06-08 | $10.71 | 1,468,500 |
| 2026-06-05 | $11.21 | 871,800 |
| 2026-06-04 | $11.83 | 1,345,700 |
| 2026-06-03 | $13.14 | 1,682,200 |
| 2026-06-02 | $12.29 | 3,111,100 |
| 2026-06-01 | $14.51 | 6,679,700 |
| 2026-05-29 | $22.70 | 2,856,600 |
| 2026-05-28 | $29.65 | 307,400 |
| 2026-05-27 | $29.61 | 297,500 |
| 2026-05-26 | $29.93 | 273,600 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
đ° Latest News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Motley Fool âĸ 2026-06-08T11:16:03Z
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals
MarketBeat âĸ 2026-05-31T21:03:56Z
OCS Stock Drops Over 23% â Eye Drop Trial For Diabetic Vision Loss Misses Target
Stocktwits âĸ 2026-05-29T20:18:13Z
Oculis Holding AG Phase 3 Trial of Potential Eye Drops for Diabetic Patients Fails to Primary Endpoint
MT Newswires âĸ 2026-05-29T19:46:41ZEtsy upgraded, ZoomInfo downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-21T13:40:17Z
Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Zacks âĸ 2026-05-11T22:05:08Z
Weighing Oculis Holding (NasdaqGM:OCS) Rich P/B Against DCF Upside After Strong Multi Year Share Gains
Simply Wall St. âĸ 2026-05-11T05:09:56Z
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-05-07T12:50:18Z
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
Zacks âĸ 2026-05-06T12:25:09Z
Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors?
Simply Wall St. âĸ 2026-04-29T18:07:45Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,031,758 | $791,469 | $1,628,765 | $7,979,093 |
| Total Expenses | $101,159,339 | $90,670,833 | $56,791,273 | $40,101,072 |
| Other Income Expense | $-22,800,239 | $-17,664,983 | $-53,207,989 | $60,692 |
| Net Non Operating Interest Income Expense | $1,160,573 | $1,893,827 | $141,201 | $-7,823,029 |
| Interest Expense Non Operating | $1,031,758 | $791,469 | $1,628,765 | $7,979,093 |
| Operating Expense | $101,159,339 | $90,670,833 | $56,791,273 | $40,101,072 |
| Other Operating Expenses | $1,467,747 | $2,555,242 | $2,250,545 | $4,133,225 |
| General And Administrative Expense | $28,731,918 | $23,435,643 | $18,237,219 | $8,351,913 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Net Interest Income | $1,160,573 | $1,893,827 | $141,201 | $-7,823,029 |
| Interest Income | $2,192,331 | $2,685,295 | $1,769,966 | $156,064 |
| Normalized Income | $-99,811,161 | $-88,611,719 | $-61,305,282 | $-47,987,065 |
| Net Income From Continuing And Discontinued Operation | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Total Operating Income As Reported | $-101,159,339 | $-90,670,833 | $-99,972,756 | $-40,101,072 |
| Net Income Common Stockholders | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Net Income | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Net Income Including Noncontrolling Interests | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Net Income Continuous Operations | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Pretax Income | $-122,799,006 | $-106,441,989 | $-109,858,062 | $-47,863,409 |
| Special Income Charges | $0 | $0 | $-43,181,483 | $0 |
| Interest Income Non Operating | $2,192,331 | $2,685,295 | $1,769,966 | $156,064 |
| Operating Income | $-101,159,339 | $-90,670,833 | $-56,791,273 | $-40,101,072 |
| Depreciation Amortization Depletion Income Statement | $253,914 | $169,689 | $78,032 | $89,180 |
| Depreciation And Amortization In Income Statement | $253,914 | $169,689 | $78,032 | $89,180 |
| Depreciation Income Statement | $253,914 | $169,689 | $78,032 | $89,180 |
| Per Share | ||||
| Diluted EPS | $-2.34 | $-2.63 | $-3.68 | $-14.02 |
| Basic EPS | $-2.34 | $-2.63 | $-3.68 | $-14.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $-42,775 | $-32,889 | $-4,522,679 | $5,159 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-98,290,730 | $-87,482,664 | $-54,665,827 | $-39,574,665 |
| Total Unusual Items | $-22,800,239 | $-17,664,983 | $-53,207,989 | $60,692 |
| Total Unusual Items Excluding Goodwill | $-22,800,239 | $-17,664,983 | $-53,207,989 | $60,692 |
| Reconciled Depreciation | $676,278 | $502,874 | $355,480 | $370,343 |
| EBITDA (Bullshit earnings) | $-121,090,969 | $-105,147,647 | $-107,873,817 | $-39,513,974 |
| EBIT | $-121,767,248 | $-105,650,521 | $-108,229,296 | $-39,884,316 |
| Diluted Average Shares | $64,708,560 | $50,047,752 | $37,033,854 | $40,543,716 |
| Basic Average Shares | $64,708,560 | $50,047,752 | $37,033,854 | $40,543,716 |
| Diluted NI Availto Com Stockholders | $-122,568,625 | $-106,243,813 | $-109,990,592 | $-47,931,532 |
| Tax Provision | $-230,381 | $-198,177 | $132,531 | $68,123 |
| Restructuring And Mergern Acquisition | $0 | $0 | $43,181,483 | $0 |
| Gain On Sale Of Security | $-22,800,239 | $-17,664,983 | $-10,026,507 | $60,692 |
| Research And Development | $70,705,761 | $64,510,259 | $36,225,478 | $27,526,755 |
| Selling General And Administration | $28,731,918 | $23,435,643 | $18,237,219 | $8,351,913 |
| Other Gand A | $10,156,560 | $9,221,413 | $9,531,065 | $2,841,360 |
| Salaries And Wages | $18,575,358 | $14,214,230 | $8,706,154 | $5,510,553 |
Fetched: 2026-06-22
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $226,389,726 | $74,429,007 | $100,973,549 | $-136,490,544 |
| Total Assets | $292,264,928 | $149,069,816 | $141,638,186 | $45,902,698 |
| Total Non Current Assets | $21,147,940 | $19,143,877 | $16,520,512 | $16,601,021 |
| Other Non Current Assets | $972,305 | $589,576 | $110,236 | $91,657 |
| Goodwill And Other Intangible Assets | $16,463,536 | $16,463,536 | $15,118,411 | $15,118,411 |
| Other Intangible Assets | $16,463,536 | $16,463,536 | $15,118,411 | $15,118,411 |
| Current Assets | $271,116,988 | $129,925,938 | $125,117,674 | $29,301,676 |
| Prepaid Assets | $5,055,985 | $5,846,215 | $10,107,016 | $3,460,662 |
| Receivables | $2,222,057 | $1,875,248 | $1,491,280 | $1,333,977 |
| Other Receivables | $1,229,935 | $779,082 | $1,085,018 | $1,129,608 |
| Taxes Receivable | $992,123 | $1,096,165 | $406,262 | $204,370 |
| Cash Cash Equivalents And Short Term Investments | $263,838,946 | $122,204,475 | $113,519,378 | $24,507,037 |
| Cash And Cash Equivalents | $100,734,498 | $34,319,265 | $47,472,010 | $24,507,037 |
| Cash Equivalents | - | $15,450,358 | $26,898,783 | - |
| Cash Financial | - | $18,868,907 | $20,573,227 | - |
| Non Current Deferred Assets | - | - | - | $29,727 |
| Non Current Deferred Taxes Assets | - | - | - | $29,727 |
| Investmentin Financial Assets | - | - | - | $61,930 |
| Debt | ||||
| Total Debt | $2,864,893 | $1,461,554 | $749,356 | $784,037 |
| Long Term Debt And Capital Lease Obligation | $2,243,113 | $1,071,393 | $533,839 | $608,155 |
| Current Debt And Capital Lease Obligation | $621,780 | $390,161 | $215,517 | $175,882 |
| Net Debt | - | - | - | $127,158,895 |
| Long Term Debt | - | - | - | $151,665,931 |
| Liabilities | ||||
| Minimum Pension Liabilities | $-2,023,880 | $-2,765,805 | $-1,327,784 | $-326,992 |
| Total Liabilities Net Minority Interest | $49,411,665 | $58,177,272 | $25,546,226 | $167,274,830 |
| Total Non Current Liabilities Net Minority Interest | $3,896,651 | $3,387,584 | $1,903,736 | $152,386,799 |
| Current Liabilities | $45,515,014 | $54,789,688 | $23,642,490 | $14,888,031 |
| Other Current Liabilities | $17,932,522 | $24,587,546 | $6,651,308 | $1,239 |
| Payables And Accrued Expenses | $21,398,138 | $25,234,098 | $13,306,332 | $8,759,414 |
| Payables | $3,387,584 | $7,335,018 | $9,508,770 | $4,789,685 |
| Other Payable | $1,158,096 | $63,169 | $100,327 | - |
| Accounts Payable | $2,229,489 | $7,271,849 | $9,408,443 | $4,789,685 |
| Tradeand Other Payables Non Current | - | $0 | $468,193 | $0 |
| Other Non Current Liabilities | - | - | - | $151,665,931 |
| Non Current Deferred Liabilities | - | - | - | $0 |
| Non Current Deferred Taxes Liabilities | - | - | - | $0 |
| Equity | ||||
| Common Stock Equity | $242,853,263 | $90,892,543 | $116,091,960 | $-121,372,133 |
| Total Equity Gross Minority Interest | $242,853,263 | $90,892,543 | $116,091,960 | $-121,372,133 |
| Stockholders Equity | $242,853,263 | $90,892,543 | $116,091,960 | $-121,372,133 |
| Other Equity Interest | $37,637,487 | $19,894,472 | $7,901,061 | $3,432,174 |
| Gains Losses Not Affecting Retained Earnings | $-2,618,411 | $-3,101,467 | $-1,732,808 | $-698,573 |
| Retained Earnings | $-476,260,925 | $-353,692,299 | $-247,448,487 | $-137,457,895 |
| Other | ||||
| Treasury Shares Number | $871,610 | $1,238,605 | - | - |
| Ordinary Shares Number | $71,819,809 | $54,080,465 | $45,394,504 | $40,543,716 |
| Share Issued | $72,691,419 | $55,319,070 | $45,394,504 | $40,543,716 |
| Tangible Book Value | $226,389,726 | $74,429,007 | $100,973,549 | $-136,490,544 |
| Invested Capital | $242,853,263 | $90,892,543 | $116,091,960 | $-121,372,133 |
| Working Capital | $225,601,974 | $75,136,250 | $101,475,184 | $14,413,645 |
| Capital Lease Obligations | $2,864,893 | $1,461,554 | $749,356 | $784,037 |
| Total Capitalization | $242,853,263 | $90,892,543 | $116,091,960 | $-121,372,133 |
| Foreign Currency Translation Adjustments | $-594,530 | $-335,662 | $-405,024 | $-371,581 |
| Treasury Stock | $8,670 | $12,386 | $0 | $1,239 |
| Additional Paid In Capital | $683,376,720 | $427,251,806 | $356,918,865 | $13,305,094 |
| Capital Stock | $727,061 | $552,418 | $453,329 | $48,306 |
| Common Stock | $727,061 | $552,418 | $453,329 | $48,306 |
| Employee Benefits | $1,653,538 | $2,316,191 | $901,704 | $112,713 |
| Non Current Pension And Other Postretirement Benefit Plans | $1,653,538 | $2,316,191 | $901,704 | $112,713 |
| Long Term Capital Lease Obligation | $2,243,113 | $1,071,393 | $533,839 | $608,155 |
| Current Capital Lease Obligation | $621,780 | $390,161 | $215,517 | $175,882 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,562,575 | $4,577,884 | $3,469,332 | $5,951,497 |
| Current Accrued Expenses | $18,010,554 | $17,899,079 | $3,797,563 | $3,969,729 |
| Net PPE | $3,712,099 | $2,090,765 | $1,291,865 | $1,390,953 |
| Accumulated Depreciation | $-1,113,506 | $-1,002,031 | $-837,297 | $-682,471 |
| Gross PPE | $4,825,605 | $3,092,796 | $2,129,162 | $2,073,425 |
| Leases | $220,472 | $121,383 | $0 | - |
| Other Properties | $3,918,946 | $2,391,746 | $1,700,605 | $1,682,025 |
| Machinery Furniture Equipment | $686,187 | $579,667 | $428,557 | $391,399 |
| Properties | $0 | $0 | $0 | - |
| Other Short Term Investments | $163,104,448 | $87,885,211 | $66,047,368 | $0 |
| Investments And Advances | - | - | - | $61,930 |
| Duefrom Related Parties Current | - | - | - | - |
Fetched: 2026-06-22
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-83,843,643 | $-60,876,192 | $-68,228,551 | $-35,451,349 |
| Operating Activities | ||||
| Operating Cash Flow | $-82,124,459 | $-60,591,313 | $-68,169,098 | $-31,056,779 |
| Cash Flow From Continuing Operating Activities | $-82,124,459 | $-60,591,313 | $-68,169,098 | $-31,056,779 |
| Operating Gains Losses | $15,352,508 | $19,192,183 | $4,037,852 | $-11,147 |
| Investing Activities | ||||
| Capital Expenditure | $-1,719,184 | $-284,879 | $-59,453 | $-4,394,570 |
| Investing Cash Flow | $-75,473,151 | $-19,920,483 | $-65,612,617 | $-4,394,570 |
| Cash Flow From Continuing Investing Activities | $-75,473,151 | $-19,920,483 | $-65,612,617 | $-4,394,570 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $221,535,634 | $66,316,145 | $167,973,404 | $2,514,368 |
| Financing Cash Flow | $231,517,551 | $66,854,938 | $160,555,399 | $2,122,969 |
| Cash Flow From Continuing Financing Activities | $231,517,551 | $66,854,938 | $160,555,399 | $2,122,969 |
| Net Other Financing Charges | $-16,376,834 | $-3,584,523 | $-9,401,011 | $-343,094 |
| Cash Dividends Paid | $0 | $0 | $0 | - |
| Net Common Stock Issuance | $221,535,634 | $66,316,145 | $167,973,404 | $0 |
| Common Stock Issuance | $221,535,634 | $66,316,145 | $167,973,404 | $0 |
| Net Preferred Stock Issuance | - | $0 | $0 | $2,514,368 |
| Preferred Stock Issuance | - | $0 | $0 | $2,514,368 |
| Other | ||||
| Repayment Of Debt | $-462,000 | $-339,378 | $-195,700 | $-196,938 |
| End Cash Position | $100,734,498 | $34,319,265 | $47,472,010 | $24,507,037 |
| Beginning Cash Position | $34,319,265 | $47,472,010 | $24,507,037 | $57,318,919 |
| Effect Of Exchange Rate Changes | $-7,504,707 | $504,112 | $-3,808,710 | $517,737 |
| Changes In Cash | $73,919,940 | $-13,656,858 | $26,773,684 | $-33,329,619 |
| Interest Paid Cff | $-107,759 | $-66,885 | $-56,976 | - |
| Proceeds From Stock Option Exercised | $26,928,509 | $4,529,578 | $2,235,682 | $148,633 |
| Net Issuance Payments Of Debt | $-462,000 | $-339,378 | $-195,700 | $-196,938 |
| Net Long Term Debt Issuance | $-462,000 | $-339,378 | $-195,700 | $-196,938 |
| Long Term Debt Payments | $-462,000 | $-339,378 | $-195,700 | $-196,938 |
| Interest Received Cfi | $1,537,109 | $1,825,704 | $1,533,393 | - |
| Net Investment Purchase And Sale | $-75,291,076 | $-21,461,307 | $-67,086,557 | $0 |
| Purchase Of Investment | $-75,291,076 | $-21,461,307 | $-67,086,557 | $0 |
| Net Intangibles Purchase And Sale | $-1,346,364 | $0 | $0 | $-4,314,061 |
| Purchase Of Intangibles | $-1,346,364 | $0 | $0 | $-4,314,061 |
| Net PPE Purchase And Sale | $-372,820 | $-284,879 | $-59,453 | $-80,509 |
| Purchase Of PPE | $-372,820 | $-284,879 | $-59,453 | $-80,509 |
| Taxes Refund Paid | $-68,123 | $-188,268 | $-125,099 | $-24,772 |
| Change In Working Capital | $-91,657 | $17,539,884 | $-16,090,716 | $7,429,152 |
| Change In Other Working Capital | $-138,724 | $-117,667 | $-35,920 | - |
| Change In Other Current Assets | $2,909,483 | $6,169,491 | $-6,881,689 | $-2,224,534 |
| Change In Payables And Accrued Expense | $-2,411,564 | $11,182,125 | $-9,217,698 | $9,841,955 |
| Change In Payable | $-2,411,564 | $11,182,125 | $-9,217,698 | $3,769,075 |
| Change In Account Payable | $-2,411,564 | $11,650,318 | $-9,685,890 | $3,769,075 |
| Change In Receivables | $-450,852 | $305,935 | $44,590 | $-188,268 |
| Other Non Cash Items | $4,933,363 | $-3,312,030 | $49,042,561 | $8,015,012 |
| Stock Based Compensation | $19,872,177 | $12,116,033 | $4,468,886 | $995,838 |
| Depreciation Amortization Depletion | $676,278 | $502,874 | $355,480 | $370,343 |
| Depreciation And Amortization | $676,278 | $502,874 | $355,480 | $370,343 |
| Depreciation | $676,278 | $502,874 | $355,480 | $370,343 |
| Pension And Employee Benefit Expense | $125,099 | $-44,590 | $-211,801 | $-11,147 |
| Gain Loss On Investment Securities | $15,227,409 | $19,236,773 | $4,249,653 | - |
| Net Income From Continuing Operations | $-122,799,006 | $-106,441,989 | $-109,858,062 | $-47,863,409 |
| Interest Received Cfo | - | $1,825,704 | $1,533,393 | $156,064 |
| Interest Paid Cfo | - | $-66,885 | $-56,976 | $-123,860 |
| Change In Accrued Expense | - | $13,765,855 | $-14,304,648 | $6,072,880 |
| Net Foreign Currency Exchange Gain Loss | - | - | $-37,158 | $722,107 |
| Change In Prepaid Assets | - | - | - | - |
Fetched: 2026-06-22